Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment

Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of the disease cannot be predicted with certainty. It is crucial to regularly monitor the disease using multiple assessments to evaluate its progression. Currently, there is no consensus on the exact definition of disease progression. Although nintedanib and pirfenidone can slow down the progression of IPF, the disease can still advance even under anti-fibrotic treatment. The aim of this review is to examine and summarize the current data regarding IPF progression in patients receiving anti-fibrotic treatment, while also highlighting the limitations of the tests used for assessing disease progression